suzhou
(6)
John Li and the company that changed hands for a dollar
Before SalubrisBio opened its Maryland laboratory, John Li transferred its shares for $1. His path from scientist to founder runs through two countries, a ribbon cutting, and a later encounter with a bank willing to lend against ideas.
Liu Jianqiang Built a Company Around the Part Nobody Sees
Before an X-ray becomes an image, a detector has to catch what passes through. Liu Jianqiang made that overlooked layer the center of a 19-year engineering company.
Zhengrong Ying Spent a Career Seeing Inside Things. Then He Built a Company Around the View.
From a prize-winning computer-vision poster in Boston to a CT company in Suzhou, Zhengrong Ying’s career is a study in one patient idea: better images can change what people are able to see, decide and build.
Virtue Diagnostics
Virtue Diagnostics is a platform-based in vitro diagnostics (IVD) company headquartered in Singapore, with manufacturing in Suzhou, China and clinical operations in Beijing. Founded in 2019, it develops affordable diagnostic instruments and reagents across chemiluminescence, clinical chemistry, hematology, clinical mass spectrometry, multiplex immunohistochemistry (mIHC) and molecular diagnostics, aiming to serve patients through every stage of disease - from early screening and diagnosis to treatment monitoring and minimal residual disease management. Its strategy centers on localized innovation and expansion in emerging markets including China, Singapore, Brazil, Indonesia and the Philippines. The company closed a US$100 million Series B round in January 2022 led by Sequoia China and Morningside Ventures.
克睿基因 Cure Genetics
克睿基因 Cure Genetics is a clinical-stage biotech founded in Suzhou in 2016 that develops cell and gene therapies for solid tumors and genetic diseases. It runs two proprietary platforms: AIMS, an allogeneic CAR-NKT cell therapy approach aimed at hard-to-treat solid tumors, and VELP, a directed-evolution AAV vector platform that builds high-quality viral libraries for tissue-targeted gene delivery to the nervous system, heart, and kidney. Its lead programs include CGC729 (anti-CD70 CAR-NKT for renal cell carcinoma) and CGC-602 (a PD-1-IL-2v bispecific antibody).
Keythera Pharmaceuticals Co., Ltd
Keythera (Suzhou) Biopharmaceuticals is a clinical-stage biotech building first-in-class small molecule drugs for cancer and autoimmune disease. Its core edge is ADMS - Affinity Detection by Mass Spectroscopy - an affinity-based high-throughput screening platform that can screen up to 250,000 compounds per day per workstation and fuses bioinformatics, structural chemistry, computer-aided drug design and AI to find and optimize drug candidates faster and at lower risk. Founded in 2020 by industry veteran Dr. Yongqi Deng, the company has built six pipelines, advanced its lead EP4 antagonist KF-0210 into the clinic, and raised roughly RMB 100M in Series A funding.